Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Hold at StockNews.com

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Monday.

ASND has been the subject of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $152.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday. Bank of America increased their price objective on Ascendis Pharma A/S from $107.00 to $113.00 in a research note on Thursday. Wedbush increased their price objective on Ascendis Pharma A/S from $187.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, September 6th. Morgan Stanley increased their price objective on Ascendis Pharma A/S from $109.00 to $113.00 and gave the company an “equal weight” rating in a research note on Wednesday, September 6th. Finally, Wells Fargo & Company dropped their price objective on Ascendis Pharma A/S from $139.00 to $134.00 and set an “overweight” rating for the company in a research note on Wednesday, September 6th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.20.

Ascendis Pharma A/S Price Performance

ASND traded up $2.48 during midday trading on Monday, hitting $100.06. The stock had a trading volume of 446,081 shares, compared to its average volume of 467,287. The company has a market cap of $5.74 billion, a P/E ratio of -8.85 and a beta of 0.50. The business has a fifty day moving average of $92.25 and a 200 day moving average of $93.16. The company has a debt-to-equity ratio of 7.39, a quick ratio of 3.32 and a current ratio of 3.52. Ascendis Pharma A/S has a 1 year low of $64.33 and a 1 year high of $134.52.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the business. Candriam S.C.A. boosted its holdings in shares of Ascendis Pharma A/S by 31.5% during the 1st quarter. Candriam S.C.A. now owns 250,375 shares of the biotechnology company’s stock valued at $24,709,000 after buying an additional 60,000 shares in the last quarter. Avoro Capital Advisors LLC raised its position in Ascendis Pharma A/S by 8.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 3,100,000 shares of the biotechnology company’s stock worth $378,603,000 after buying an additional 250,000 shares during the last quarter. Parkwood LLC grew its stake in shares of Ascendis Pharma A/S by 6.4% during the 1st quarter. Parkwood LLC now owns 18,678 shares of the biotechnology company’s stock valued at $2,003,000 after purchasing an additional 1,125 shares during the period. Tamarack Advisers LP grew its stake in shares of Ascendis Pharma A/S by 200.0% during the 4th quarter. Tamarack Advisers LP now owns 45,000 shares of the biotechnology company’s stock valued at $5,496,000 after purchasing an additional 30,000 shares during the period. Finally, First Republic Investment Management Inc. grew its stake in shares of Ascendis Pharma A/S by 682.2% during the 4th quarter. First Republic Investment Management Inc. now owns 117,323 shares of the biotechnology company’s stock valued at $14,329,000 after purchasing an additional 102,323 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.